# Mixed Adenoneuroendocrine Carcinoma (MANEC) of the Stomach: A Case Report in a 52‐Year‐Old Male Following Total D2 Gastrectomy

## TL;DR

A rare stomach cancer called MANEC has worse survival rates than typical gastric cancer and requires more aggressive treatment.

## Contribution

This case report highlights the clinical behavior and management challenges of gastric MANEC following surgery.

## Key findings

- MANEC has poorer disease-free survival compared to conventional adenocarcinoma.
- MANEC is associated with a higher risk of distant recurrence after treatment.
- Post-recurrence survival is worse in MANEC than in clear adenocarcinoma.

## Abstract

Gastric MANEC (gMANEC) is a rare tumor composed of at least 30% each adenocarcinoma and neuroendocrine carcinoma (NEC) components. A 52‐year‐old male underwent total D2 gastrectomy for gastric cancer. Final pathology revealed MANEC. We compare outcomes and mortality rates between gastric MANEC and conventional adenocarcinoma. MANEC has poorer disease‐free survival (DFS) and post‐recurrence survival (PRS), and higher risk of distant recurrence, compared with clear adenocarcinoma. Rigorous follow‐up and adjuvant therapy tailored to the more aggressive component are advised.

Gastric MANEC is a special type of gastric cancer with pathologic characteristics that affect the overall outcome and survival of the patient and clinicians must be aware of it in order to be prepared for the most proper oncologic manipulation.